Evidence map›Paper›PMID 41346580›Full record

ReviewFrontiers in immunology2025

The "double-edged sword" effect of cytokines in cancer: coexisting opportunities and challenges.

Xuan Yin, Wangzheqi Zhang, Guanhua Wang, Yawei Liu, Bing Dai, Liping Yue

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. IL1B-Expressing Exhausted CD4Cancer genomics & proteomics
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuan Yin *Department of Nursing, Institute of International Medical Science and Technology, Shanghai Sanda University, Shanghai, China.
Wangzheqi Zhang *Naval Medical University, Shanghai, China.
Guanhua Wang *Anhui Medical University, Hefei, China.
Yawei Liu *Naval Medical University, Shanghai, China.
Bing DaiNaval Medical University, Shanghai, China.
Liping YueDepartment of Nursing, Institute of International Medical Science and Technology, Shanghai Sanda University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

As a key signaling molecule network in the tumor immune microenvironment, cytokines mediate intercellular communication through mechanisms such as autocrine and paracrine, exhibiting a significant "double-edged sword" effect during tumor initiation and progression. The dynamic regulation of this dual effect is influenced by the dependence on concentration, the variability within the tumor immune microenvironment, and the stages of tumor progression, ultimately representing the prolonged co-evolutionary result between tumors and the immune system. Cytokines, as a vital element of the immune microenvironment within tumors, influence cancer promotion by creating intricate networks. Therefore, disrupting this balance to alter the tumor growth environment is of great significance for achieving tumor suppression. In terms of clinical translation, the combined strategy of cytokine therapy and immune checkpoint blockade therapy has significantly improved treatment efficacy by synergistically enhancing immune activation and relieving immune suppression. Meanwhile, approaches such as monoclonal antibodies and bispecific molecules targeting pro-tumor cytokines have provided new insights for overcoming therapeutic resistance. In-depth clarification of the molecular mechanisms underlying the dual effects of cytokines, and breaking through the limitations of single targets from a network perspective, will provide a new paradigm for cancer immunotherapy from basic mechanisms to clinical applications. This will promote the upgrading of targeting strategies towards "dynamic regulation and synergistic intervention," ultimately improving the prognosis of cancer patients.

Indexed as

CytokinesNeoplasmsTumor MicroenvironmentAnimalsHumansImmune Checkpoint InhibitorsImmunotherapySignal TransductionCytokinesImmune Checkpoint Inhibitorscancercancer therapycytokinesimmune checkpoint blockadetumor immune microenvironment

Identifiers

PMID41346580
PMCPMC12672462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.